A Blog from the Lymphoma Program at Weill Cornell Medicine and NewYork-Presbyterian
Dr. Richard Furman Discusses the Approval of Ibrutinib for the Treatment of Patients with Waldenstrom’s Macroglobulinemia
In this Onc Live video, Dr. Richard Furman, Director of the CLL Research Center discusses the findings of a recent study that led to the approval of ibrutinib as a mono-therapy for patients with Waldenstrom’s Macroglobulinemia.
A full listing of open clinical trials for Waldenstrom’s Macroglobulinemia can be found here.
Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.
View all posts by lymphomaprogram